Healthcare Industry News: TELCYTA
News Release - March 20, 2006
Telik Announces Appointment of Michael K. Inouye as Senior Vice President of Commercial OperationsPALO ALTO, Calif., March 20 (HSMN NewsFeed) -- Telik, Inc. (Nasdaq: TELK ) announced the appointment of Michael K. Inouye as Senior Vice President, Commercial Operations.
Mr. Inouye has held positions of increasing responsibility first at Merck & Co., Inc., and then at Gilead Sciences, Inc. He was associated with Gilead from 1995 to 2004, most recently as Senior Vice President, Commercial Operations (Worldwide). Mr. Inouye led the commercial introduction of Gilead's first four products and was responsible for building and managing the company's global sales, marketing, training, pricing, access and reimbursement programs and international operations. While at Gilead, Mr. Inouye was also responsible for the launch and commercialization of several important new pharmaceuticals, growing net sales from $6 million in 1998 to $1.2 billion in 2004.
"We welcome Mr. Inouye to our senior leadership team as we prepare for Telik's transition from a cancer drug research and development organization to a commercial entity focused on making new oncology drugs available to the broadest appropriate patient populations," said Michael M. Wick, M.D., Ph.D., Chairman and Chief Executive Officer. "Mike brings to Telik an outstanding record in creating, leading and growing commercial biopharmaceutical organizations that have successfully introduced novel small molecule drugs for serious diseases."
"I am very pleased and excited to join Telik at such an important time for the company," Mr. Inouye said. "In particular, I look forward to participating in the formation of a commercial organization that complements the robust product candidate pipeline led by TELCYTA® and TELINTRA(TM)."
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases. The company's most advanced drug development candidate is TELCYTA (TLK286), a tumor-activated small molecule product candidate that is in Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.